Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bremzalerbart, an antibody targeting Bet v 1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Belrestotug, an antibody targeting TIGIT.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Becotatug, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Atisnolerbart, an antibody targeting Bet v 1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Siltartoxatug, an antibody targeting Clostridium tetani tetanus toxin (TeNT).

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sigvotatug, an antibody targeting ITGB6.

Alligator Bioscience 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Cantargia 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Almirall 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Esteve 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Minoryx Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Oryzon Genomics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.